EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

B7-H3 as a Reliable Diagnostic Biomarker for the Differentiation of High-Grade Gliomas (HGGs) and Low-Grade Gliomas (LGGs)

Fatima Juković-Bihorac, Slaviša Đuričić iD, Emir Begagić iD, Hakija Bečulić, Alma Efendić, Semir Vranić iD, Mirza Pojskić iD

Brain Sciences · 15.08.2025 · 15 (8) · 872

DOI: 10.3390/brainsci15080872 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain Sciences, online erschienen am 15.08.2025. Verfasst von Fatima Juković-Bihorac und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Cantonal Hospital Zenica, Crkvice 67, 72000 Zenica, Bosnia and Herzegovina. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: This study aimed to evaluate the diagnostic and prognostic utility of B7-H3 expression in differentiating low-grade gliomas (LGGs) from high-grade gliomas (HGGs) and to examine its association with clinical outcomes.

Methods

This retrospective study included 99 patients with histopathologically confirmed gliomas (42 LGGs and 57 HGGs). B7-H3 expression was assessed using immunohistochemistry and scored by immunoreactive score (IRS).

Results

B7-H3 expression was significantly higher in HGG compared to LGG (p < 0.001). The total IRS (B7-H3 A × B) demonstrated strong discriminative power (AUC = 0.816). High B7-H3 expression independently predicted disease progression (OR = 4.9, 95% CI: 2.4–10.1; p < 0.001) and was associated with IDH wild-type status and elevated Ki-67 index. Patients with high B7-H3 had significantly shorter overall survival (median 6 months vs. 42 months) and progression-free survival (median 3 months vs. 25 months) (both p < 0.001). Cox regression confirmed high B7-H3 as an independent predictor of mortality (HR = 2.9, 95% CI: 1.7–4.7; p < 0.001) and progression (HR = 2.6, 95% CI: 1.6–4.2; p < 0.001).

Conclusions

B7-H3 expression is a reliable biomarker for distinguishing HGG from LGG and is independently associated with worse survival outcomes. Its assessment may aid in glioma classification and prognostication.

Schlagwörter

Stichwörter der Autor:innen

B7-H3 proteinbrain neoplasmsgliomashigh-grade gliomasimmunohistochemistrylow-grade gliomasprognosis

Autor:innen und Institutionen

  • Department of Pathology, Cantonal Hospital Zenica, Crkvice 67, 72000 Zenica, Bosnia and Herzegovina.
  • Department of Pathology, Faculty of Medicine, University of Zenica, Travnička 1, 72000 Zenica, Bosnia and Herzegovina.
  • Department of Pathology, Faculty of Medicine, University of Banja Luka, Save Mrkalja 14, 78000 Banja Luka, Bosnia and Herzegovina.
  • Department of Neurosurgery, Cantonal Hospital Zenica, Crkvice 67, 72000 Zenica, Bosnia and Herzegovina.
  • Department of Anatomy, Faculty of Medicine, University of Zenica, Travnička 1, 72000 Zenica, Bosnia and Herzegovina.
  • Department of Radiology, Faculty of Medicine, University of Zenica, Travnička 1, 72000 Zenica, Bosnia and Herzegovina.

ORCID-Profile: Slaviša Đuričić, Emir Begagić, Semir Vranić, Mirza Pojskić

Zitieren

APA

Juković-Bihorac, F., Đuričić, S., Begagić, E., Bečulić, H., Efendić, A., Vranić, S., & Pojskić, M. (2025). B7-H3 as a Reliable Diagnostic Biomarker for the Differentiation of High-Grade Gliomas (HGGs) and Low-Grade Gliomas (LGGs). Brain Sciences, 15(8), 872. https://doi.org/10.3390/brainsci15080872

Vancouver

Juković-Bihorac F, Đuričić S, Begagić E, Bečulić H, Efendić A, Vranić S, et al. B7-H3 as a Reliable Diagnostic Biomarker for the Differentiation of High-Grade Gliomas (HGGs) and Low-Grade Gliomas (LGGs). Brain Sciences. 2025;15(8):872. doi:10.3390/brainsci15080872

BibTeX
@article{JukoviBihorac2025,
  author = {Juković-Bihorac, Fatima and Đuričić, Slaviša and Begagić, Emir and Bečulić, Hakija and Efendić, Alma and Vranić, Semir and Pojskić, Mirza},
  title = {B7-H3 as a Reliable Diagnostic Biomarker for the Differentiation of High-Grade Gliomas (HGGs) and Low-Grade Gliomas (LGGs)},
  journal = {Brain Sciences},
  year = {2025},
  volume = {15},
  number = {8},
  pages = {872},
  doi = {10.3390/brainsci15080872}
}
Kostenlos starten →